Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease
April 15, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease –High...
Silence Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
April 07, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference 7 April 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a...
Silence Therapeutics Reports Full-year 2020 Results
March 30, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Reports Full-year 2020 ResultsAdvancing clinical programmes; On-track for three phase 1 data readouts in 2021 30 March 2021 LONDON, Silence Therapeutics plc, AIM: SLN and...
Silence Therapeutics to Present at the Barclays Global Healthcare Conference
March 04, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics to Present at the Barclays Global Healthcare Conference 4 March 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the...
Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases
February 26, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases Silence to receive $2 million research milestone...
Silence Therapeutics to Participate in March Investor Conferences
February 22, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics to Participate in March Investor Conferences 22 February 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery,...
Silence Therapeutics to Present at the 2021 SVB Leerink Global Healthcare Conference
February 18, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics to Present at the 2021 SVB Leerink Global Healthcare Conference 18 February 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a...
Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a)
February 17, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a) 17 February 2021 LONDON, Silence Therapeutics plc, AIM: SLN and...
Silence Therapeutics plc Announces $45 Million Private Placement
February 05, 2021 07:00 ET
|
Silence Therapeutics plc
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN...
Silence Therapeutics Appoints Craig Tooman as Chief Financial Officer
January 06, 2021 07:00 ET
|
Silence Therapeutics plc
Silence Therapeutics Appoints Craig Tooman as Chief Financial Officer 6 January 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the...